Superworth

Cartesian Therapeutics EPS RNAC

Diluted earnings per share by quarter and over the last twelve months, from 2015.

Last 12 months, to Jun 30, 2026
−$5.94
Latest quarter, Q2 FY26
$0.46
−8% on a year earlier
Fiscal year 2025
−$5.12

Cartesian Therapeutics' earnings per share was −$5.94 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $0.46, down 8% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$5.12n/a
FY2024−$11.49n/a
FY2023−$48.87−1005%
FY2022$5.40n/a
FY2021−$8.40n/a
FY2020−$20.70n/a
FY2019−$36.60n/a
FY2018−$87.30n/a
FY2017−$96.30n/a
FY2016−$254.10n/a
FY2015−$453.60n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.46−8%−$5.94
Q1 FY26−$1.46n/a−$5.90
Q4 FY25−$3.56n/a−$5.12
Q3 FY25−$1.38n/a−$1.96
Q2 FY25$0.50−7%−$1.71
Q1 FY25−$0.68n/a−$1.67
Q4 FY24−$0.40n/a−$11.49
Q3 FY24−$1.13n/a−$51.75
Q2 FY24$0.54n/a−$52.36
Q1 FY24−$10.50n/a−$55.13
Q4 FY23−$40.66−1606%−$48.87
Q3 FY23−$1.74n/a−$5.51

Against its peers

Companies in Drug Manufacturers - General nearest Cartesian Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
RNACCartesian Therapeutics−$5.94
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
ARVNArvinas$0.16
SPROSpero Therapeutics$0.11
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
ATNMActinium Pharmaceuticals$0.36
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Cartesian Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.